Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

570articles mentioning diseases

2,756disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: SLE ×

SLE

This disease is selected. Its supporting articles are shown below.

Articles mentioning SLE

570 articles · page 36 of 48

PT4:03 Effect of cenerimod, an S1P1 modulator, on fatigue in SLE: results from the phase 2 care study

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

90.9%

autoimmune disease SLE systemic lupus erythematosus Lupus cenerimod NCT03742037

…S1PR1 receptor modulator with potential therapeutic benefits in autoimmune disease. The Phase 2b CARE study ( NCT03742037) evaluated the efficacy …

PT4:04 Achievement of low disease activity and remission in patients with SLE treated with dapirolizumab pegol: updated 48-week analyses from a phase 3 trial including lower glucocorticoid dose criteria

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

93.9%

SLE Lupus dapirolizumab pegol DZP NCT04294667 prednisone PBO

…Results Baseline characteristics reflected a moderate-to-severe SLE population ( table 1). To Week 48, greater proportions of patie…

PT4:08 Impact of clinically important improvements in patient-reported outcomes on disease activity in patients with systemic lupus erythematosus treated with upadacitinib or placebo

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

98.9%

SLE SLEek FACIT-fatigue PROs upadacitinib PBO UPA

…ht the potential multifaceted benefits of UPA for patients with SLE.…

PT5:03 SLE methylation risk score: divergent associations with SLE features compared to a polygenic risk score and its link to HLA-DRB1*03:01

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

99.3%

SLE SLE-non-HLA SLE-PRS nephritis Simoa

…study investigated the relationship between a methylation-based SLE risk score (MRS), a non-HLA SLE polygenic risk score (SLE-PRS),…

PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis of anifrolumab trials

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

99.6%

SLE lupus SLE-DAS LupusQoL anifrolumab BILAG-2004 AstraZeneca EQ-5D SLEDAI-2K SLEDAI

…ifrolumab trials (MUSE, TULIP-1, TULIP-2) in moderate-to-severe SLE. Physicians’ assessments (clinical and laboratory data, BILAG-2…

PT7:05 Defining the lupus low disease activity state(LLDAS) using the British Isles lupus assessment group index (BILAG-2004): a prospective cohort study

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

91.1%

SLE Lupus prednisolone SLEDAI-2K University College London Hospital SLEDAI-LLDAS

…individual patients from the University College London Hospital SLE Cohort (2011-2024) were used to determine BILAG-LLDAS and SLEDA…

S16:02 A supported 4- or 7- week live-online programme is more effective than standard care for fatigue management of systemic lupus erythematosus patients in the United Kingdom

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

89.6%

Systemic Lupus Erythematosus Systemic Lupus SLE FLIP Study

…ne fatigue management programmes (FMPs) in patients living with Systemic Lupus Erythematosus (SLE) in the United Kingdom.Methods Here we present preliminary…

S1:05 Cutaneous lupus subtypes: the tissue response influences the phenotype

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

81.6%

Cutaneous Lupus erythematosus SLE CDLE SCLE acute LE

…Objectives Cutaneous Lupus erythematosus (CLE) presents with different subtypes including chronic LE for…

S7:04 Predictors of sustained drug-free remission in systemic lupus erythematosus (SLE). Data from the SLICC (systemic lupus international collaborating clinics) inception cohort

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

99.6%

SLE prednisone methylprednisolone antimalarials

…ictors thereof have not been fully evaluated.Methods We studied SLE patients in a long-term longitudinal, multinational, multiethni…

Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data

lupusscimed · abstract · 2026-02-15 · 3 matching annotations

98.0%

SLE cutaneous lupus erythematosus CLE

…-specific recurrence occurred in a large group of patients with SLE.…

Self-management experiences of patients with systemic lupus erythematosus in China: a qualitative study

bmjopen · abstract · 2026-02-06 · 3 matching annotations

83.2%

systemic lupus erythematosus SLE

…gate the self-management experiences of individuals living with systemic lupus erythematosus (SLE) through the lens of the Capability, Opportunity, and Moti…

Practical insights for the clinical implementation of the EULAR recommendations for patients with systemic lupus erythematosus

rmdopen · abstract · 2025-12-31 · 3 matching annotations

88.3%

lupus nephritis systemic lupus erythematosus SLE glucocorticoids biologics GCs immunosuppressants

…ns for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for practitioners on diagnosis, moni…